$PPCB

$0.42▲ +2.4% YTD

5 SEC 13D/G filings tracked · Last updated Oct 14, 2026

Filing History

CP $0.42▲ +2.4%Oct 14, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pan…

News

PPCB ▲ +2.0% - Propanc Biopharma, Inc.

CP $0.50▲ +2.0%Oct 7, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution M…

News

PPCB ▲ +7.9% - Propanc Biopharma, Inc.

CP $0.68▲ +7.9%Sep 22, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015…

News

PPCB ▼ -1.0% - Propanc Biopharma, Inc.

CP $1.00▲ -1.0%Sep 9, 2026 · ThinkSabio Blog

$PPCB - Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027…

News

PPCB ▲ +177.6% - Propanc Biopharma, Inc.

CP 2.97▲ +177.6%Aug 27, 2026 · ThinkSabio Blog

$PPCB Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Surviva…